Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
45 studies found for:    OKT3
Show Display Options
Rank Status Study
1 Unknown  Oral OKT3 in Combination With Beta-D-Glucosylceramide
Condition: Healthy
Interventions: Drug: OKT3;   Drug: OKT3, GC;   Drug: GC
2 Active, not recruiting Oral OKT3 for the Treatment of Active Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: Oral OKT3
3 Completed Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Conditions: Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes
Interventions: Biological: muromonab-CD3;   Biological: natural killer cell therapy;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: thiotepa;   Genetic: gene expression analysis;   Other: flow cytometry;   Other: immunologic technique;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Radiation: total-body irradiation
4 Active, not recruiting Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
Condition: Hematologic Malignancies
Interventions: Drug: Clofarabine;   Procedure: Stem Cell Transplantation, Hematopoietic;   Other: OKT3;   Drug: Thiotepa;   Drug: Melphalan;   Drug: Mycophenolate mofetil;   Drug: Rituximab;   Other: G-CSF
5 Unknown  Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis
Condition: Myocarditis
Interventions: Drug: Muromonab-CD3;   Drug: Cyclosporine
6 Completed Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis
Conditions: Myocarditis;   Giant Cell Myocarditis
Interventions: Drug: Cyclosporine;   Drug: methylprednisolone;   Drug: Muromonab-CD3;   Drug: prednisone
7 Completed Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome
Condition: Nonalcoholic Steatohepatitis
Intervention: Drug: OKT3
8 Unknown  Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: antibody therapy;   Biological: biological therapy;   Biological: muromonab-CD3;   Drug: cyclophosphamide
9 Recruiting HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplasia;   Chronic Myeloid Leukemia;   Histiocytosis
Interventions: Drug: Chemotherapy and antibodies;   Device: Miltenyi Biotec CliniMACS;   Procedure: Allogeneic stem cell transplantation
10 Completed Biological Therapy in Treating Women With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Biological: Aldesleukin;   Biological: Sargramostim;   Biological: therapeutic autologous lymphocytes
11 Terminated Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: muromonab-CD3;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methylprednisolone;   Procedure: allogeneic bone marrow transplantation
12 Unknown  Lymphocyte Therapy in Treating Patients With Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: aldesleukin;   Biological: muromonab-CD3;   Biological: therapeutic autologous lymphocytes;   Procedure: adjuvant therapy
13 Completed Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: aldesleukin;   Biological: muromonab-CD3;   Biological: therapeutic tumor infiltrating lymphocytes;   Procedure: conventional surgery
14 Completed Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: aldesleukin;   Biological: autologous tumor cell vaccine;   Biological: muromonab-CD3;   Biological: sargramostim;   Biological: therapeutic autologous lymphocytes;   Procedure: surgical procedure;   Radiation: radiation therapy
15 Completed Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: autologous tumor cell vaccine;   Biological: muromonab-CD3;   Biological: therapeutic autologous lymphocytes;   Procedure: surgical procedure
16 Completed Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
Condition: Hematologic Malignancies
Interventions: Drug: Fludarabine;   Drug: Thiotepa;   Drug: Melphalan;   Drug: OKT-3;   Procedure: CD3/CD19 depletion on CliniMACS
17 Completed Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
Condition: Melanoma
Interventions: Drug: IL-2;   Drug: gp100:209-217;   Drug: OKT3;   Drug: rF-go 100P209;   Drug: Montanide ISA 51
18 Terminated Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
Condition: Kidney Neoplasms
Interventions: Drug: IL-2 (interleukin-2);   Drug: OKT3;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Mesna
19 Active, not recruiting Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia
Condition: Lymphoblastic Leukemia, Acute, Childhood;
Interventions: Drug: VP16;   Radiation: TBI;   Drug: VP16, ATG;   Drug: Fludarabine, OKT3, Treosulfan, Thiotepa
20 Active, not recruiting ALL-SCT BFM International- HSCT in Children and Adolescents With ALL
Condition: Lymphoblastic Leukemia, Acute, Childhood;
Interventions: Drug: VP16;   Radiation: TBI;   Drug: VP16, ATG;   Drug: Fludarabine, OKT3, Treosulfan, Thiotepa;   Drug: VP16,  ATG

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years